tbuckley/cabot-search huggingface dataset:
DESQUAMATION IN THE COURSE OF TYPHOID FEVER.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial
Authors: Federica Grosso, Nicola Steele, Silvia Novello, Anna Nowak, Sanjay Popat, Laurent Greillier, Ute von Wangenheim, Nassim Morsli, Jose Barrueco, Giorgio Scagliotti
Journal: Annals of Oncology (2017)
Lithopaedion
Authors: J. B. Fraser
Journal: BMJ (1913)

lIe was seen .again.at 11.30.p.m. and at 9 the next miiorning, an.d oni neitlher occasionl was there any clhange.Dr. 'Maclinlay saw hiim at 3 p.m., wlhen lhe was sleeping.At 5 p.m. lhe got out of bed to try to get relief, and was ngiain seized witlh intenise pain, starting in the abdomen anld shootinig tllrouiglh to the back and uip the right side.lie was, seen-agaill abouit 6 p.m., wlhen lhe was moaninlg a good (leal; ani(d tUFr1iD(1 hiim over in bed to examili-ine himi at olnce aggravated the pain, wlichl w-as then miiainly over the base of the riglt lung.At 7.30 hie was seen by Dr. Weeles.Thrle was then miarlkzed dullniess at the base of the right lung, witlh absence of breath souinds.Thlere was miiarlke(d puilsation in. the epigastriuiml, but nio mnurm-ur.Up to this point we were in favotur of rLuptured duodenal uilcer into the lesser sac, but tllo evidence was lnot suffi- CiClit.Dr. Weeks did at onie time think of aneurysm as a diagnosis, butt as the patient's conditioni w%vas not improved lie was remiioved to the infirmary, Midldlesbrougb, wlhere lie was seen by M1r.Dicliie at 9 p.m.After examininig the patienit Mr. Dicliie was unable to arrive at a diagnosis, except that it mniglht be somne earlv clhest condclition, and advised nio operation.Tlle patient gradually became weaker, and died at 7 a.m. on November 4th.A p)ost-mitortem examination was made the same after-
Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.
Authors: Moshe Talpaz, Hagop Kantarjian, Neil P. Shah, Nicholas Donato, John Nicoll, Stephen A. Bai, Fei Huang, Edwin Clark, Arthur P. DeCillis, Charles Sawyers
Journal: Blood (2004)
From the Food and Drug Administration
Authors: S. L. Nightingale
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Resolution of non-alcoholic steatohepatitis and hepatic fibrosis by sodium glucose transporter-2 inhibitor, ipragliflozin; a multicenter randomized controlled trial
Authors: Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, Michihiro Nonaka, Hideyuki Hyogo, Hideki Fujii, Tomoaki Nakajima, Kento Imajo, Kenichi Tanaka, Yoshihito Kubotsu, Hiroshi Isoda, Satoshi Oeda, Osamu Kurai, Masato Yoneda, Masafumi Ono, Yoichiro Kitajima, Ryo Tajiri, Ayako Takamori, Atsushi Kawaguchi, Shinichi Aishima, Masayoshi Kage, Keizo Anzai, Atsushi Nakajima, Yuichiro Eguchi
Journal: Journal of Hepatology (2020)
Single-cell analysis of RORα tracer mouse lung reveals ILC progenitors and effector ILC2 subsets
Authors: Maryam Ghaedi, Mona Orangi, Itziar Martinez-Gonzalez, Lisa Wei, Xiaoxiao Lu, Arundhoti Das, Alireza Heravi-Moussavi, Marco A. Marra, Fumio Takei
Journal: The Journal of Experimental Medicine (2019)

Lung group 2 innate lymphoid cells (ILC2s) drive allergic inflammation and promote tissue repair. ILC2 development is dependent on the transcription factor retinoic acid receptor–related orphan receptor (RORα), which is also expressed in common ILC progenitors. To elucidate the developmental pathways of lung ILC2s, we generated RORα lineage tracer mice and performed single-cell RNA sequencing, flow cytometry, and functional analyses. In adult mouse lungs, we found an IL-18Rα+ST2− population different from conventional IL-18Rα−ST2+ ILC2s. The former was GATA-3intTcf7EGFP+Kit+, produced few cytokines, and differentiated into multiple ILC lineages in vivo and in vitro. In neonatal mouse lungs, three ILC populations were identified, namely an ILC progenitor population similar to that in adult lungs and two distinct effector ILC2 subsets that differentially produced type 2 cytokines and amphiregulin. Lung ILC progenitors might actively contribute to ILC-poiesis in neonatal and inflamed adult lungs. In addition, neonatal lung ILC2s include distinct proinflammatory and tissue-repairing subsets.
JUST WORDS
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).
Authors: Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Alexander David Guminski, Shahneen Kaur Sandhu, Michael Paul Brown, Tracy Liaw, Maria Gonzalez, Jill Davison, Elizabeth J. Paton, Richard A Scolyer, Louise Emmett, Grant A. McArthur
Journal: Journal of Clinical Oncology (2016)

TPS9591 Background: Clinical trials have shown that nivolumab and the combination of nivolumab and ipilimumab improve response rates and progression-free survival (PFS) compared with ipilimumab in pts with metastatic melanoma, however pts with active brain metastases were excluded. We sought to determine the antitumour activity and safety of nivolumab and nivolumab combined with ipilimumab in pts with active melanoma brain metastases (NCT02374242). Methods: This open-label, multisite ph 2 study consists of 3 cohorts. Cohorts 1 (n = 30) and 3 (n = 30) include pts with active melanoma brain metastases with no prior local therapy to the brain and are asymptomatic from the brain metastases. Eligible pts are randomised to either cohort 1: nivolumab only (3mg/kg Q2W) or cohort 3: nivolumab (1mg/kg Q3W x 4, then 3mg/kg Q2W) combined with ipilimumab (3mg/kg Q3W x 4). Cohort 2 (n = 16) includes pts with brain metastases who have either 1) failed local therapy with evidence of intracranial progression (new +/- progressed in previously treated lesions), 2) neurological symptoms related to brain metastases or 3) leptomeningeal disease. Pts with prior treatment with anti-PD1/PDL1/PDL2/CTLA4 therapies are excluded. Pts must have ≥ 1 brain metastasis that measure ≥ 5mm and ≤ 40mm as per RECIST 1.1 by MRI + gadolinium. FET-PET is performed at baseline, wk 6 and wk 12. MRI brain and extracranial CT scans are performed at baseline, 6 wkly until wk 24, and 12 wkly thereafter. The primary endpoint is the best intracranial response ≥ wk 12. Secondary endpoints include best extracranial response, best overall response, intracranial PFS, extracranial PFS, overall PFS and overall survival, as well as safety and tolerability. Cohort 2 completed enrolment in May 2015. 18 and 15 pts have been enrolled in cohort 1 and 3 respectively as of Jan 2015. The data, safety and monitoring board reviewed the study in Dec 2015 and recommended the trial continue as planned. Recruitment is expected to be complete by Oct 2016. Thereafter, an additional two cohorts of nivolumab combined with stereotactic radiosurgery ( ≤ 4 brain metastases) or whole brain radiotherapy ( > 5 brain metastases) will be recruited. Clinical trial information: NCT02374242.
Infectious mononucleosis in the preschool child
Authors: K. A. Starling
Journal: JAMA (1968)

<h3>To the Editor:—</h3> In "Sulfobromophthalein" (<b>202</b>:979, 1967) Dr. Charm states that "normal results from a sodium sulfobromophthalein test (BSP) effectively rule out varices [esophageal] as a source of bleeding [upper gastrointestinal]." The BSP and other liver function tests, however, may be normal in hemorrhage from esophageal varices secondary to<i>extrahepatic</i>portal venous block, eg, acquired portal venous thrombosis.
TRYPANOSOMA DISEASE.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PLAGUE.
Journal: JAMA (1899)

Fear has been expressed in various newspaper editorials and despatches, that the appearance of plague in Egypt is only a precursor of its invasion of Europe—not that there will be an inefficient quarantine against Egyptian infected ports, but that the steady advance westward of the disease, of which its foothold in Egypt is only an indication, is not likely to be checked unless more rigid and concerted international measures are adopted to check its progress. The Mecca pilgrimage is stated as one great source of danger, and a still more eastern gateway is said to be afforded through the Persian Gulf, where the English sanitary regulations are said to be sadly neglected. It is certain that the range of the epidemic has been widened, increasing the possible sources of contagion, and that a rigid sanitary cordon on land is much more difficult to make effective than a quarantine at seaports,
Tranquilizer control
Authors: A. Kaufman
Journal: JAMA (1972)

A comprehensive program to reduce the distribution of tranquilizing drugs was established in a clinic serving an American Indian population of 6,000. Clinic staff, patients, and other community physicians were informed about the general problem of tranquilizer drug abuse. Individual counseling, written material, and mental health referrals were helpful in freeing patients from drug use. The program yielded a 52% decrease in tranquilizing pills dispensed from the clinic and a 33% decrease in the total number of prescriptions written for these drugs.
Sonderbände zur Strahlentherapie.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maternal Impressions.
Authors: A. G. Belsheim
Journal: JAMA (1903)

Aikin, Mich., March 14, 1903. <h3>To the Editor:</h3> —Baby S., a healthy seven-pound female baby, was born at full term on March 1, 1903. She has a prominent birthmark covering the left thumb and upper part of the arm, over the shoulder and slightly down the back. The mother had an accident three months before delivery. She was wearing an outing-flannel gown, the left sleeve of which was lighted from a match, and in a flash an area of the sleeve corresponding to the baby's birthmark was burned.
Evidence for more benefits of cholesterol-lowering drugs
Authors: A. A. Skolnick
Journal: JAMA (1997)

CLINICAL STUDIES have shown that cholesterol-lowering drugs—such as the statin class of pharmaceuticals—can dramatically reduce the risks of myocardial infarction (MI) and mortality from heart disease. Accumulating evidence suggests that these agents do more than just lower cholesterol to protect patients at risk for coronary artery disease. The evidence suggests the drugs may help reduce inflammation at the site of the plaque, reduce the risk of thrombosis, help normalize endothelial function, and improve the vessels' vasodilatory function. Speaking at the "Summit on Cholesterol and Coronary Disease: The 2nd National Conference on Lipids in the Elimination and Prevention of Coronary Artery Disease," in Lake Buena Vista, Fla, B. Greg Brown, MD, PhD, professor of medicine and cardiology and director of the University of Washington School of Medicine's Atherosclerosis Research Laboratory, in Seattle, described some of these mechanisms that may lie behind the drugs' ability to protect coronary arteries. <h3>Lipid Depletion</h3> By
Announcement: National Protect Your Hearing Month — October 2016
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

October is National Protect Your Hearing Month, a time to raise awareness about the causes and prevention of noise-induced hearing loss. Noise-induced hearing loss results from sounds in the environment that are too loud and can damage sensitive structures in the inner ear, even with a brief exposure. This type of hearing loss can result from occupational noise exposures, leisure activities such as sporting events or concerts, or use of personal listening devices. Noise-induced hearing loss is permanent and cannot be reversed (1).
Primary Localized Amyloidosis of the Seminal Vesicles and Vas Deferens
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3631: Development of targeted nanoformulation of talazoparib for combined chemoradiation therapy in lung cancer
Authors: Bijay Singh, Mostafa Abdelhalim, Stephanee Warrington, Srinivas Sridhar
Journal: Cancer Research (2019)

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy exploits a synthetic lethality strategy in cancers with inherent damage in DNA repair or transcription pathways. Talazoparib is a potent PARPi that is currently indicated for oral inhibitor therapy in several cancer clinical trials. Oral administration of these inhibitors typically results in poor bioavailability and tumor accumulation. In contrast, nanoparticle formulation provides a safe vehicle for parenteral administration of therapeutic drugs with sustainable release reducing systemic toxicity and also protect from surveillance of immune cells, thereby increasing the bioavailability of the drugs in vivo. Moreover, targeting strategy for the nanoparticles will improve the accumulation of drugs in the tumors. Here, we developed a targeted formulation of Talazoparib (NanoTLZ) which was decorated with anti-EGFR antibody as a ligand to ameliorate the cellular uptake of NanoTLZ via EGFR-mediated endocytosis. In vitro tests showed that NanoTLZ is more effective in cell growth inhibition than free Talazoparib. When combined with radiation with different doses from 2-10Gy, NanoTLZ showed a strong radiosensitization effect as evidenced with almost no colonies formation at 6 Gy of radiation dose. The high therapeutic efficacy of combined chemoradiation therapy in Calu 6 cell line can be attributed to the higher accumulation of NanoTLZ in the cancer cells as compared to the free Talazoparib which is also marred with efflux of the drug from the cells. The slow and sustained release of Talazoparib from nanoparticle formulation inside the cells lead enhanced inhibition of DNA repair pathways. These studies provide very encouraging results to evaluate the efficacy of these nanoparticles in lung cancer animal models. Citation Format: Bijay Singh, Mostafa Abdelhalim, Stephanee Warrington, Srinivas Sridhar. Development of targeted nanoformulation of talazoparib for combined chemoradiation therapy in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3631.
Book Review Man in Structure and Function . By Fritz Kahn, M.D. Translated from the German and edited by George Rosen, M.D. 2 vol. 8°, cloth, Vol. 1, 341 pp., with 207 illustrations, and Vol. 2, 397 pp., with 253 illustrations. New York: Alfred A. Knopf, 1943. $10.00 (set).
Journal: New England Journal of Medicine (1943)
Cardiopulmonary Resuscitation
Authors: J T Niemann
Journal: New England Journal of Medicine (1992)

CARDIOPULMONARY arrest can be defined as the abrupt cessation of spontaneous and effective ventilation and systemic perfusion (circulation). Cardiopulmonary resuscitation (CPR) provides artificial ventilation and circulation until advanced cardiac life support can be provided and spontaneous cardiopulmonary function restored. Patients most likely to benefit from CPR (i.e., to be successfully resuscitated) include the following: those with witnessed sudden arrest due to ventricular fibrillation outside the hospital, when electrical countershock can be performed within approximately seven to eight minutes; hospitalized patients with primary ventricular fibrillation and ischemic heart disease; those with cardiac arrest in the absence of life-threatening coexisting conditions; and . . .